Passage Bio is a genetic medicines company that specializes in developing therapies for central nervous system diseases. The company has multiple proprietary gene therapies in development to treat various conditions, such as infantile GM1, FTD-GRN, infantile Krabbe disease, metachromatic leukodystrophy, amyotrophic lateral sclerosis, and Charcot-Marie-Tooth Type 2A. Passage Bio has research collaborations with the University of Pennsylvania's Gene Therapy Program and development agreements with Catalent Maryland.